Abstract, Results, line 2 which previously read: Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04).
The author would like to make the below changes in the original article which was incorrectly published.
Page 751, Abstract, Results, line 2 which previously read: Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04).
Should read: Although median tumor size was similar between groups, the median tumor number was significantly higher in the S-TACE versus TACE-alone group (7 vs. 4, P \ 0.01).
Page 751, Abstract, Results, line 9 which previously read:
Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone.
Should read: Median PFS (189 vs. 106 days, P \ 0.01) and median overall survival time (861 vs. 467 days, P \ 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Of the 95 patients, 24 patients who were previously nonresponsive responsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).
Should read: Of the 95 patients, 24 patients who were previously nonresponsive to TACE were treated with TACE followed by sorafenib (S-TACE group), and 71 patients who were responsive to TACE were treated with TACE alone (TACE-alone group).
Page 754, Section 3, 2nd column, line 10 which previously read:
The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (2 [1] [2] [3] Should read:
The median number (range) of prior treatments was also significantly higher in the S-TACE group than in the TACE-alone group in terms of both TACE (3 [range [2] [3] [4] vs. 2 [range 2-3], P \ 0.01) and radiofrequency ablation (4 [range [1] [2] [3] [4] [5] vs. 1 [range 0-3], P \ 0.01).
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